For research and educational purposes only. Not medical advice.

NAD+ Reference

Educational, not medical advice reference for NAD+: Nootropic, Longevity, Metabolic; regulatory status, evidence posture, source review, and sch…

Reference summary

Cellular NAD+ levels decline with age, and animal models show that restoring NAD+ improves mitochondrial function and several aging biomarkers (Verdin 2015 Science review; Rajman 2018 Cell Metabolism in-vivo NAD-boosting review). Human evidence for the INJECTABLE NAD+ at the indications people use it for (longevity, addiction recovery, chronic fatigue, post-viral fatigue) is limited to small open-label series and a handful of registered ClinicalTrials.gov studies; no large outcome trial supports those indications. Most positive human pharmacokinetic data is on the oral precursors NMN and NR rather than on injectable NAD+ itself.

Regulatory and posture

Categories
Nootropic, Longevity, Metabolic
Aliases
Nicotinamide adenine dinucleotide, NAD, NAD+ infusion, NAD+ injection, IV NAD, SubQ NAD+
Evidence posture
translational - Mechanism and animal data are real; human evidence for injectable NAD+ at the community-cited indications is sparse. Compounded preparations are not FDA-approved and quality varies by source. Infusion-rate side effects (chest pressure, flushing, anxiety, nausea) are widely reported and clinics typically slow the drip to manage them.
Regulatory status
No FDA-approved injectable NAD+ drug label exists. The intravenous and subcutaneous NAD+ marketed by IV-therapy clinics and research-chemical sellers is compounded; the FDA has not approved any NAD+ product for anti-aging, addiction recovery, neurodegenerative disease, chronic fatigue, or any other community-cited indication. Distinct from the oral NAD+ precursors NMN and NR catalogued separately.
Content review status
research reference

Selected public sources

Related tools